Amoy Diagnostics Co., Ltd. (SHE:300685)
China · Delayed Price · Currency is CNY 20.54
-1.79 (-8.02%)
Apr 28, 2026, 3:04 PM CST
Amoy Diagnostics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,187 | 1,104 | 1,034 | 832.43 | 908.12 |
Other Revenue | 10.39 | 4.64 | 9.99 | 9.75 | 8.91 |
| 1,198 | 1,109 | 1,044 | 842.18 | 917.03 | |
Revenue Growth (YoY) | 8.01% | 6.27% | 23.91% | -8.16% | 25.90% |
Cost of Revenue | 219.19 | 181.34 | 176.92 | 153.44 | 147.19 |
Gross Profit | 978.54 | 927.61 | 866.58 | 688.74 | 769.84 |
Selling, General & Admin | 396.29 | 418.83 | 384.71 | 360.44 | 364.31 |
Research & Development | 177.59 | 216.11 | 203.22 | 174.53 | 156.12 |
Other Operating Expenses | 11.4 | 4.66 | 4.07 | 3.14 | 4.18 |
Operating Expenses | 592.86 | 650.35 | 597.12 | 545.1 | 534.79 |
Operating Income | 385.68 | 277.25 | 269.46 | 143.64 | 235.05 |
Interest Expense | -1.93 | -1.34 | -1.2 | -0.99 | -0.38 |
Interest & Investment Income | 39.76 | 26.58 | 19.17 | 6.11 | 5.59 |
Currency Exchange Gain (Loss) | -6.85 | 2.42 | 8.25 | 25.32 | -9.48 |
Other Non Operating Income (Expenses) | -19.08 | -18.45 | -0.33 | -2.08 | -0.48 |
EBT Excluding Unusual Items | 397.58 | 286.46 | 295.35 | 171.99 | 230.3 |
Gain (Loss) on Sale of Investments | 0.71 | -8.71 | -15.69 | 1.98 | 5.85 |
Gain (Loss) on Sale of Assets | 0.49 | -1.06 | -0.96 | 94.58 | -1.96 |
Asset Writedown | -2.84 | -0.06 | -0.04 | -0.61 | -0.27 |
Other Unusual Items | 14.99 | 13.26 | 16.19 | 18.15 | 18.06 |
Pretax Income | 410.92 | 289.88 | 294.86 | 286.08 | 251.98 |
Income Tax Expense | 49.67 | 35.02 | 33.37 | 21.79 | 12.95 |
Earnings From Continuing Operations | 361.26 | 254.86 | 261.48 | 264.29 | 239.02 |
Minority Interest in Earnings | - | - | - | -0.55 | 0.55 |
Net Income | 361.26 | 254.86 | 261.48 | 263.74 | 239.57 |
Net Income to Common | 361.26 | 254.86 | 261.48 | 263.74 | 239.57 |
Net Income Growth | 41.74% | -2.53% | -0.86% | 10.09% | 32.86% |
Shares Outstanding (Basic) | 397 | 398 | 396 | 394 | 399 |
Shares Outstanding (Diluted) | 401 | 398 | 396 | 394 | 399 |
Shares Change (YoY) | 0.80% | 0.51% | 0.65% | -1.41% | -0.36% |
EPS (Basic) | 0.91 | 0.64 | 0.66 | 0.67 | 0.60 |
EPS (Diluted) | 0.90 | 0.64 | 0.66 | 0.67 | 0.60 |
EPS Growth | 40.63% | -3.03% | -1.49% | 11.67% | 33.33% |
Free Cash Flow | 294.6 | 301.64 | 253.85 | 70.75 | 93.61 |
Free Cash Flow Per Share | 0.73 | 0.76 | 0.64 | 0.18 | 0.23 |
Dividend Per Share | 0.450 | 0.300 | 0.150 | 0.140 | 0.128 |
Dividend Growth | 50.00% | 100.00% | 7.14% | 9.55% | -7.99% |
Gross Margin | 81.70% | 83.65% | 83.05% | 81.78% | 83.95% |
Operating Margin | 32.20% | 25.00% | 25.82% | 17.06% | 25.63% |
Profit Margin | 30.16% | 22.98% | 25.06% | 31.32% | 26.13% |
Free Cash Flow Margin | 24.60% | 27.20% | 24.33% | 8.40% | 10.21% |
EBITDA | 429.88 | 329.31 | 322.24 | 191.46 | 271.49 |
EBITDA Margin | 35.89% | 29.70% | 30.88% | 22.73% | 29.61% |
D&A For EBITDA | 44.2 | 52.05 | 52.78 | 47.82 | 36.45 |
EBIT | 385.68 | 277.25 | 269.46 | 143.64 | 235.05 |
EBIT Margin | 32.20% | 25.00% | 25.82% | 17.06% | 25.63% |
Effective Tax Rate | 12.09% | 12.08% | 11.32% | 7.62% | 5.14% |
Revenue as Reported | 1,198 | 1,109 | 1,044 | 842.18 | 917.03 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.